Lipid-based nanocarriers for oral peptide delivery☆

Purpose: Peptide and protein therapeutics are highly potent but mostly require parenteral administration because they are degraded in the gastrointestinal tract, poorly permeate the intestinal epithelium, and have low oral bioavailability. Lipid-based nanocarriers are a promising strategy to enable oral peptide delivery by protecting cargo, enhancing permeability, reducing proteolysis, and promoting lymphatic transport.

Hypothesis: If peptides/proteins are incorporated into appropriately designed lipid-based nanocarriers—solid lipid nanoparticles, emulsions, self-emulsifying systems, nanocapsules, or liposomes—with optimized lipid composition, particle size, surface charge, and polymer/surfactant coatings, then they can survive GI conditions, cross the mucus and intestinal barriers, and produce improved oral pharmacokinetics and pharmacodynamics.

Aims: Overview lipid-based nanostructures designed for oral peptide/protein delivery. - Analyze how composition and physicochemical properties—particle size, zeta potential, drug loading, release—affect interaction with the GI environment. - Compare PK/PD performance of SLNs, micro/nanoemulsions, SEDDS/SMEDDS/SNEDDS, nanocapsules, and liposomes. - Highlight key factors determining success and remaining challenges for commercial oral peptide delivery.

Delivery system: Platforms: solid lipid nanoparticles (SLNs); microemulsions and nanoemulsions; self-emulsifying drug delivery systems (SEDDS, SMEDDS, SNEDDS); nanocapsules (NC); liposomes; also hybrid lipid–polymer systems, niosomes, and archaeosomes. - Payloads: peptides/proteins such as insulin, salmon calcitonin (sCT), leuprolide, octreotide, GLP-1 analogues, parathyroid hormone, heparin, desmopressin, albumin, lysozyme, and others. - Key lipids/excipients: triglycerides (LCT/MCT), mono-/di-/triglycerides, fatty acids, fatty alcohols, phospholipids, bile salts, surfactants, PEG derivatives, chitosan, alginates, pectins, and acrylic polymers. - Functionalization/targeting: lectins, goblet-cell CSK ligand, octaarginine (r8), chitosan coatings, PEGylation, mucoadhesive polymers. - Mechanisms exploited: increased intestinal membrane permeability, reduced proteolytic degradation, increased intestinal lymphatic transport, mucodiffusion, and controlled release.

Approach: Review and synthesis of in vitro, ex vivo, and in vivo literature. In vitro models include Caco-2 cells, simulated gastric/intestinal fluids, and mucus diffusion assays. In vivo models include rats, mice, dogs, and human clinical studies. Disease contexts include diabetes, osteoporosis, acromegaly, and other peptide-responsive conditions. As a review, it reports no primary experimental groups, n values, doses, or controls.

Key methods: No primary methods. The review discusses data generated by cited studies using: - Entrapment efficiency (AE) and drug loading (DL) measurements. - In vitro release and stability in simulated GI fluids. - Caco-2 permeability, tight-junction, and mucodiffusion assays. - Particle size, zeta potential, and colloidal stability characterization. - In vivo PK/PD: plasma glucose, calcium, hormone levels, bioavailability, and hypoglycemic duration. - Clinical trial readouts for oral peptide formulations.

Key results: Protein/peptide therapeutic market projected at $180 billion by 2018. - SLNs achieved insulin AE up to 97.8% and DL up to 18.92%; sCT AE ~90%; leuprolide AE ~75%. - Micro/nanoemulsions achieved >80% entrapment for insulin, sCT, and BSA; some W/O/W systems reached >95%. - Nanocapsules achieved >90% AE for OVA, BSA, insulin, and D-Lys6-GnRH; final loading often modest (~2%). - Liposomes achieved >90% AE for insulin and sCT; peptide release controlled by bilayer rigidity, cholesterol, and coatings. - In vivo: PBCA insulin NC produced long-term hypoglycemia in diabetic rats at 12.5 or 50 IU/kg; chitosan–alginate insulin NC showed pharmacological bioavailability 8.42% (25 IU/kg) and 5.72% (50 IU/kg) in normal rats, and 8.19% / 7.84% in diabetic rats. - Lectin-modified insulin liposomes: 9.12% bioavailability (50 IU/kg) in diabetic mice. - Fusogenic liposomes: 8.4% bioavailability (10 IU/kg) after intracolonic administration. - r8-modified SLN: 13.86% insulin pharmacological availability (25 IU/kg, intraduodenal). - sCT-loaded SLN: up to 12.41% absolute bioavailability (250 IU/kg, intraduodenal). - Microemulsion for glycoprotein IIb/IIIa antagonist: 27% bioavailability; earthworm fibrinolytic enzyme: 17.55%. - SMEDDS: rhPTH1-34 absolute bioavailability 5.4% in rats; leuprolide bioavailability increased 6.5-fold, and 17.2-fold with hydrophobic ion pairing. - Colonic delivery: insulin SGC enteric capsules 5.73% BA in rats; calcitonin PA increased to 6.2% from 2.1% in dogs; sodium caprate minispheres 22.3% absolute BA after intracolonic administration from 7.0% in rats. - Clinical: heparin GIPET absolute BA 3.9–7.6% in humans; desmopressin BA 2.4% from 0.2% in humans; Octreolin relative oral BA similar to SC injection with efficacy up to 13 months.

Interpretation: The authors conclude that lipid-based nanocarriers can improve peptide entrapment, protect against enzymatic degradation, prolong GI residence, and enhance intestinal permeation. They argue that successful oral peptide delivery will require multifunctional systems combining protease inhibitors, permeation enhancers, modified-release technology, and optimized lipid excipients. More mechanistic studies and standardized in vitro/in vivo models are needed to improve clinical translation.

Limitations: Review article; no primary data, effect sizes, n values, doses, or controls. - Most studies remain preclinical; clinical data for hydrophilic peptides are scarce. - Limited mechanistic understanding of nanocarrier–peptide–intestinal milieu interactions. - Lack of uniform in vitro/in vivo models and poor in vitro–in vivo correlation. - Lipid nanocarriers may be digested by gastric/pancreatic enzymes; dilution can cause leakage or precipitation. - Surfactants, bile salts, and synthetic polymers may cause concentration-dependent toxicity. - Mucus layer and enzymatic barriers remain major obstacles. - Commercial success is mostly limited to hydrophobic peptides such as cyclosporine; hydrophilic peptide products remain challenging.